Diabetic Neuropathy Global Market Report 2024 Market Size, Trends, Outlook, Overview 2024-2033

"The new report published by The Business Research Company, titled ""Diabetic Neuropathy Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the diabetic neuropathy market size has grown strongly in recent years. It will grow from $5.4 billion in 2023 to $5.85 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The diabetic neuropathy market size is expected to see strong growth in the next few years. It will grow to $8.42 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp

Rising Diabetes Prevalence Sparks Growth In Diabetic Neuropathy Market
The rising prevalence of diabetes is expected to boost the growth of the diabetic neuropathy market going forward. Diabetes is a persistent disorder where the body struggles to use and store glucose appropriately (a type of sugar). Diabetes occurs when the body either does not create enough insulin (a hormone that aids in blood sugar regulation) or does not use insulin effectively. Diabetic neuropathy is a type of nerve injury that can occur in diabetics with d different forms of nerve damage causing different symptoms. For instance, in August 2022, according to the IDF Diabetes Atlas report published by the International Diabetes Federation, a Belgium-based global diabetes community and an umbrella organization of over 230 national diabetes associations, 6.7 million deaths were attributed to diabetes in the year 2021, which is equivalent to one death every five seconds. There are currently 537 million adults (aged 20-79) living with diabetes, or 1 in 10 people. It is estimated that this number will increase to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic neuropathy market.

Artificial Intelligence Meets Pain Relief: Nevro Corporation's Senza Hfx Iq For Diabetic Neuropathy
Major companies operating in the diabetic neuropathy market are focused on providing innovative solutions to strengthen their position in the market. For instance, in July 2021, Nevro Corporation, a US-based medical device company, developed Senza (also known as """"HFX""""), a high spinal cord stimulation technology for the treatment of painful diabetic neuropathy (PDN), a condition that affects up to one-third of people with diabetes (PWDs) in the United States and causes loss of sensation and pain in the lower limbs. Senza® HFX iQTM is the next generation technology that uses artificial intelligence to optimise and maintain pain alleviation based on each patient's response. It was designed to take into consideration how different people experience pain and to help patients achieve and maintain long-term pain relief and an improved quality of life. The Senza HFX iQ system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, will be the first to use algorithms built specifically for treating chronic back and leg pain, such as severe diabetic neuropathy and non-surgical back pain.

The diabetic neuropathy market covered in this report is segmented -

1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
2) By Drug Class: Analgesics, Anti-Depressants, Anti-consulvants, Other Drug Classes
3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments
4) By Distribution Channel: Online Distribution, Offline Distribution
5) By End-user: Hospitals, Specialty Clinics, Other End-users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9057&type=discount

Major companies operating in the diabetic neuropathy market report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Daiichi Sankyo Company Limited, Johnson & Johnson, Glenmark Pharmaceuticals Limited, Depomed Inc., Astellas Pharma Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Abbott Laboratories, Lupin Limited, Novartis AG, Boehringer Ingelheim, Janssen Pharmaceuticals Inc., Regenacy Pharmaceuticals Inc., Ionis Pharmaceuticals, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Union Chimique Belge, Zydus Cadila, Amgen Inc., Biogen Inc., Genentech Inc. .

Contents of the report:
1. Executive Summary
2. Diabetic Neuropathy Market Report Structure
3. Diabetic Neuropathy Market Trends And Strategies
4. Diabetic Neuropathy Market - Macro Economic Scenario
5. Diabetic Neuropathy Market Size And Growth
…..
27. Diabetic Neuropathy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.